Pluristem Therapeutics Inc (PSTI)

[Auto1]

Pluristem Therapeutics: Questionable Ethics And Bucket Shop Coverage

Seeking Alpha
Feb. 2, 2015 4:37 PMPluristem Therapeutics Inc. (PSTI)CVM, EVSNF, FLUX

Summary

Pluristem has a long history of ethically questionable reporting to investors.

Stock price jumps ostensibly on analysis published by a discredited bucket shop.

Heavy dilution is imminent and could have a significant negative effect on the share price.

Top executives have zero educational and professional experience in the biotech field.

The author has not reached out to PSTI management for comments. Phone calls made to Acceleron Equity Research were not returned.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) is a clinical-stage company engaged in development of cell therapy products for the treatment of life threatening diseases. Since Jan 28th, Pluristem has jumped over 30% on no material news except for one-page coverage update from Acceleron Equity Research.